Clinical Trial Detail

NCT ID NCT02570542
Title Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Memorial Sloan Kettering Cancer Center
Indications

diffuse large B-cell lymphoma

Therapies

Plerixafor

Carmustine + Cytarabine + Etoposide + Melphalan

Age Groups: adult

No variant requirements are available.